This new CPB states that transcatheter aortic valve implantation (TAVI) by means of the Edwards Sapien transcatheter heart valve is considered medically necessary for trans-femoral delivery in persons with severe symptomatic native aortic valve stenosis who have been determined by a cardiac surgeon to be inoperable for open aortic valve replacement and in whom existing co-morbidities would not preclude the expected benefit from correction of the aortic stenosis.  TAVI is considered experimental and investigational for all other indications because its effectiveness for indications other than the one listed above has not been established.